Close Menu
Invest Insider News
    Facebook X (Twitter) Instagram
    Tuesday, November 17
    Facebook X (Twitter) Instagram Pinterest Vimeo
    Invest Insider News
    • Home
    • Bitcoin
    • Commodities
    • Finance
    • Investing
    • Property
    • Stock Market
    • Utilities
    Invest Insider News
    Home»Investing»Seres Therapeutics executive sells stock for $2,749 By Investing.com
    Investing

    Seres Therapeutics executive sells stock for $2,749 By Investing.com

    October 29, 20243 Mins Read


    CAMBRIDGE, MA—Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics, Inc. (NASDAQ:), executed a stock transaction recently, selling 3,984 shares of common stock. The shares were sold at a weighted average price of approximately $0.6901 per share, totaling $2,749. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan, primarily to cover taxes associated with the vesting of restricted stock units.

    On October 27, 2024, Henn acquired 12,622 shares of common stock without any monetary exchange, as these were part of a vesting schedule for previously granted restricted stock units. Following these transactions, Henn now holds 75,885 shares of Seres Therapeutics common stock directly.

    In other recent news, Seres Therapeutics has been the subject of multiple developments. The company’s decision to sell its VOWST business to Nestlé Health Science has been approved by shareholders. This move, which includes the transfer of the first FDA-approved orally administered microbiome therapeutic, is expected to significantly strengthen Seres Therapeutics’ financial position despite a reported net loss of $32.9 million.

    JPMorgan has downgraded Seres Therapeutics from Neutral to Underweight, citing unclear growth potential and the absence of immediate, clear growth drivers. However, TD Cowen maintains a Buy rating on the company’s shares, following positive data from the Phase 1b trial of SER-155 in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation.

    Seres Therapeutics’ shareholders have also raised concerns over the company’s rejection of a takeover bid from Nestlé S.A. and the subsequent sale of the VOWST business. The company is preparing SER-147 for IND readiness by the second half of 2025, targeting metabolic diseases. These are recent developments from Seres Therapeutics.

    InvestingPro Insights

    Recent transactions by Seres Therapeutics’ Chief Scientific Officer Matthew R. Henn highlight the company’s ongoing stock-based compensation practices. While these insider activities provide some insight into executive compensation, a broader look at Seres Therapeutics’ financial health reveals more pressing concerns for investors.

    According to InvestingPro data, Seres Therapeutics currently has a market capitalization of $131.51 million, reflecting its status as a small-cap biotech company. The firm’s financial metrics paint a challenging picture, with revenue for the last twelve months as of Q2 2023 standing at just $0.37 million, coupled with a staggering revenue decline of 99.71% over the same period.

    InvestingPro Tips indicate that Seres Therapeutics is “quickly burning through cash” and “operates with a significant debt burden.” These factors are particularly concerning for a biotech company that relies heavily on research and development to bring products to market. The company’s negative gross profit margin of -25,214.44% further underscores the financial strain it’s under.

    The stock’s performance has been notably weak, with InvestingPro data showing a 46.08% price decline over the past three months. This aligns with another InvestingPro Tip stating that the “stock has taken a big hit over the last week” and has “fared poorly over the last month.”

    For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips that could provide valuable insights into Seres Therapeutics’ investment potential. These tips, along with real-time metrics, can help in forming a more informed investment decision in the volatile biotech sector.

    This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.





    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleA Finance Bro’s Approach to Your Dating Life
    Next Article Citizens Utility Board says Peoples Gas pipeline replacement will require 7% annual rate hikes

    Related Posts

    Investing

    NZD/INR Historical Data | New Zealand Dollar Indian Rupee

    October 30, 2026
    Investing

    GBP 2 Years IRS Interest Rate Swap Bond Chart (Live Data)

    October 27, 2026
    Investing

    USD/CNY Historical Data | US Dollar Chinese Yuan

    October 25, 2026
    Leave A Reply Cancel Reply

    Top Posts

    How is the UK Commercial Property Market Performing?

    December 31, 2000

    How much are they in different states across the US?

    December 31, 2000

    A Guide To Becoming A Property Developer

    December 31, 2000
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews
    Stock Market

    Stock market outlook: Q2 results, macro data in focus; global trends and FII flows to guide investors’ sentiment this week

    November 2, 2025
    Bitcoin

    Strategy CEO Phong Le: 3 Reasons For 1st Bitcoin Sale Since 2022

    June 12, 2026
    Investing

    AI Derangement Syndrome Sparks Flight to Quality as Yields Fall

    February 27, 2026
    What's Hot

    Utilities Down on Retreat From Risk — Utilities Roundup

    December 22, 2025

    How a tiny Derbyshire village became the UK’s unlikeliest property hotspot

    August 17, 2024

    Weekly Crypto Price Prediction: Bitcoin, Ethereum and XRP

    January 4, 2026
    Most Popular

    I turned NotebookLM into my personal finance coach — and it called out my worst money habits

    December 26, 2025

    Who owns the most BTC in 2026?

    January 20, 2026

    CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

    August 15, 2024
    Editor's Picks

    Strategy’s Equity Shift Is No Retreat From Bitcoin Strategy, Benchmark Says

    September 2, 2025

    Stock Market Close: Sensex surges 630 pts, Nifty tops 23,700; Oil holds $100-mark; Fed outcome eyed | Markets News

    March 17, 2026

    China property stocks still can’t find a floor

    December 16, 2025
    Facebook X (Twitter) Instagram Pinterest Vimeo
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions
    © 2026 Invest Insider News

    Type above and press Enter to search. Press Esc to cancel.